Showing 161-170 of 214 results for "".
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://practicaldermatology.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Statins and Skin Cancer: The Latest Data
https://practicaldermatology.com/topics/skin-cancer-photoprotection/statins-and-skin-cancer-the-latest-data/20426/A look at another commonly used drug and its potential association with skin cancer risks.Managing Diaper Dermatitis
https://practicaldermatology.com/topics/pediatric/managing-diaper-dermatitis/20357/First-line treatment tips and a review of when to assess for an alternate diagnosis.Diversity in the Dermatology Workforce: What Can We Do?
https://practicaldermatology.com/topics/practice-management/diversity-in-the-dermatology-workforce-what-can-we-do/23057/Medicine in general lacks workforce diversity. Dermatology fares worse than other specialties. Here’s a closer look at the problem.Proton Pump Inhibitor-induced Dermal Hypersensitivity Reaction Masquerading as an Arthropod-bite Reaction
https://practicaldermatology.com/youngmd-connect/resident-resource-center/proton-pump-inhibitor-induced-dermal-hypersensitivity-reaction-masquerading-as-an-arthropod-bite-reaction/23940/Physician Spotlight: Anne Chapas, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-anne-chapas-md/23390/Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.